Irritation

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Research, CLD, Refractive surgery, ASCRS, Patient, Telecanthus, ARVO, University, Cataract, Abstract, Eyelid, Detail, Society, University of California, Irritation, Safety, MGD, Pain, Ophthalmic, Pharmaceutical industry

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
  • This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
  • “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
  • This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.

CYNTHIA BAILEY PARTNERS WITH KINDRA TO RAISE AWARENESS ABOUT VAGINAL HEALTH DURING MENOPAUSE

Retrieved on: 
Thursday, March 28, 2024
Health, Puberty, Weight gain, Research, Menopause, Fertility, Dry, Woman, Skin, Irritation, Personal lubricant, Bailey, Fatigue, Collection, Human, Birth control

NEW YORK, March 28, 2024 /PRNewswire/ -- Kindra , the menopause and vaginal health brand, announces actress and model Cynthia Bailey as brand ambassador to raise awareness for menopause and vaginal wellness by heightening the conversation around the sexual health of women at every age.

Key Points: 
  • NEW YORK, March 28, 2024 /PRNewswire/ -- Kindra , the menopause and vaginal health brand, announces actress and model Cynthia Bailey as brand ambassador to raise awareness for menopause and vaginal wellness by heightening the conversation around the sexual health of women at every age.
  • As long-term champions for breaking down stigmas around women's health, Bailey and Kindra share a vision to increase conversations around the vast spectrum of needs as it relates to a woman's sexual health.
  • Vaginas have no expiration date, and Kindra's array of care, solutions, and services cater to the needs of vaginal health and sexual wellness.
  • Whether it's embracing the transitions of menopause, tackling contraceptive dryness, or navigating postpartum challenges, Kindra provides women and their healthcare practitioners with clinically-backed, trusted solutions and educational resources on vaginal health and sexual wellness.

Theraderm's Cleansing Wash Honored with 'Best Post-Procedure Cleanser' Award in the 2024 NewBeauty Awards

Retrieved on: 
Tuesday, March 26, 2024
Skin care, Cleanser, Dry, MD, Skin, Irritation, Theraderm, Cosmetics

This recognition underscores Theraderm's commitment to providing innovative and effective skincare solutions that cater to a diverse range of skin types and needs.

Key Points: 
  • This recognition underscores Theraderm's commitment to providing innovative and effective skincare solutions that cater to a diverse range of skin types and needs.
  • Theraderm's Cleansing Wash is a gentle facial cleanser designed to thoroughly cleanse the skin of unwanted dirt, oil, and makeup without causing dryness or irritation.
  • Its mild, soap-free formula leaves the skin feeling smooth, soft, and refreshed, making it suitable for all skin types.
  • We thank NewBeauty for this honor and remain dedicated to meeting the diverse needs of our customers."

COSRX Announces Price Reduction on Low pH Niacinamide Micellar Cleansing Water

Retrieved on: 
Tuesday, March 26, 2024
Water, Skin care, Acne, Low, Skin, Face, Transport, Nicotinamide, Irritation, Cosmetics

In response to the ever-increasing costs in the beauty industry, COSRX is thrilled to announce a significant price reduction on its popular Low pH Niacinamide Micellar Cleansing Water .

Key Points: 
  • In response to the ever-increasing costs in the beauty industry, COSRX is thrilled to announce a significant price reduction on its popular Low pH Niacinamide Micellar Cleansing Water .
  • In response to this, COSRX formulated the Low pH Niacinamide Micellar Cleansing Water with a composition similar to the pH of skin to help maintain a healthy skin balance and strengthen the skin barrier.
  • Praised for its gentle yet efficient cleansing action, this micellar water cleanser has garnered rave reviews from users across various skin types.
  • So, by reducing the price of our Low pH Niacinamide Micellar Cleansing Water, we hope to make quality skincare more accessible to all.

KINDRA LAUNCHES FIRST-EVER COMPREHENSIVE VAGINAL HEALTH SYSTEM: THE DAILY V SYSTEM

Retrieved on: 
Monday, March 25, 2024
DPT, Testosterone, Sulfate, Urology, Hormone, Hyaluronic acid, Woman, Vaginal lubrication, FACOG, Libido, Arousal, Paraben, Dry, MD, Itch, Vaginitis, WCS, Skin, Pelvic floor, Stinger, Irritation, Medicine, Personal lubricant, Pain, BCB-PMD, Orgasm, Birth control

NEW YORK, March 25, 2024 /PRNewswire/ -- Today, Kindra, the sex-positive vaginal health brand, announced the launch of the first-ever comprehensive vaginal health product system - the Daily V System. The 4-part daily regimen of Kindra products includes: Daily Vaginal Lotion, V Relief Serum, Soothe Bath Soak and the Core Supplement meant to support vulvar and vaginal skin for optimal vaginal health and sexual wellness.

Key Points: 
  • NEW YORK, March 25, 2024 /PRNewswire/ -- Today, Kindra , the sex-positive vaginal health brand, announced the launch of the first-ever comprehensive vaginal health product system - the Daily V System .
  • The 4-part daily regimen of Kindra products includes: Daily Vaginal Lotion , V Relief Serum , Soothe Bath Soak and the Core Supplement meant to support vulvar and vaginal skin for optimal vaginal health and sexual wellness.
  • This hormone-free system is designed to provide targeted relief and support for daily vulvar and vaginal health needs.
  • As part of its launch of the Daily V System, Kindra has partnered with pelvic floor physical therapist Dr. Sara Reardon, known online as The Vagina Whisperer, on a video about the importance of a daily vaginal health regimen for long-term vulvovaginal health and comfort.

Sleep Doctor Survey Finds 1 in 7 U.S. Travelers Have Encountered Mattresses Infested With Bed Bugs in the Past Year

Retrieved on: 
Wednesday, March 20, 2024
Education, Anxiety, Travel, Momentive (software company), Sleep, Slumber (film), Irritation, Skin, Biting, Hotel

SEATTLE, March 20, 2024 /PRNewswire-PRWeb/ -- Sleep Doctor, the leading online source for sleep health, improvement, and education, has published a report that investigates how prevalent bed bugs are in paid accommodations. The report also shares insight into how bed bugs impact travelers. Researchers gathered and analyzed responses from 1,565 travelers in the United States who have stayed overnight in paid accommodations this past year.    

Key Points: 
  • Although I haven't had a bed bug case from a high-end property in the last year, I know they are out there because bed bugs are challenging to eliminate."
  • According to the survey, 14% of U.S. travelers say they have come across bed bugs this past year.
  • Thirty-two percent of travelers did not realize there were bed bugs until after they had slept in the bed, while 68% realized beforehand.
  • Others stayed in the same accommodations on a different bed, some slept on the floor, and some proceeded to sleep in the bed bug-infested bed.

#PatThePeptide TikTok Challenge Sparks Surge in Demand: COSRX's The 6 Peptide Skin Booster Serum Sells Out Across Platforms within One Week

Retrieved on: 
Wednesday, March 20, 2024
Cream, Absorption, Hyperpigmentation, Serum, Risk, Gland, Vitamin, Ulta, Skin, Irritation, Peptide, Vaccine

Aimed at spotlighting COSRX's hero product, The 6 Peptide Skin Booster Serum, the campaign shows how the brand has made skincare more accessible to everyone.

Key Points: 
  • Aimed at spotlighting COSRX's hero product, The 6 Peptide Skin Booster Serum, the campaign shows how the brand has made skincare more accessible to everyone.
  • In response to overwhelming demand, COSRX TikTok Shop US and COSRX.com have announced that The 6 Peptide Skin Booster Serum is now back in stock.
  • "We are thrilled to witness the immense enthusiasm and passion generated by the #PatThePeptide TikTok challenge," said a COSRX representative.
  • The 6 Peptide Skin Booster Serum is currently available for purchase on COSRX TikTok Shop US and COSRX.com .

INTRODUCING BYOMA BODY

Retrieved on: 
Wednesday, March 13, 2024
PHA, TIME, Face, Cell, Hyperpigmentation, Science, Microbiota, Complex, Inflammation, NMF, Dermis, Red, Skin, Ceramide, Love, BLUE, Irritation, BETA, Sphingolipid, Cholesterol, Dicarboxylic acid, Gland, Itch, Cosmetics

NEW YORK, March 13, 2024 /PRNewswire/ -- BYOMA BODY is here to disrupt and democratize the bodycare category in the same way we revolutionized skincare – bringing best-in-class barrier care and skin-compatible science below the neck. This is accessible, affordable, and approachable barrier care for the rest of you – targeted, clinically efficacious, sensorial formulas for your best body.

Key Points: 
  • BYOMA Body is here to change that.
  • Skin does not have a uniform composition, so we are more likely to experience different issues on our body than on our faces.
  • BYOMA has carefully studied the science of skin – breaking down the barrier from the lipid layer to the microbiome.
  • This is a breakthrough in skin science that delivers the same level of care to your body as you show your face.

Herbal medicinal product: MyrrhaArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Ethanol, Ulcer, Inflammation, Patient, Monograph, Committee, Boil, Herbal medicine, Date, Skin, Irritation, Commiphora, Medicine, Medicinal plants

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of myrrh.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing myrrh.
  • Herbal medicines containing this myrrh preparation are usually available in liquid forms to be applied to the skin or the lining of the mouth.
  • Myrrh preparations may also be found in combination with other herbal substances in some herbal medicines.

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

Retrieved on: 
Thursday, March 7, 2024
Type 1, Allergy, SAN, Anxiety, EMA, Caregiver, CRL, New Drug Application, ARS, FDA, Food, Larynx, University of South Florida, Anaphylaxis, Vomiting, Entrepreneurship, Symantec Endpoint Protection, Angioedema, University, Event, Tongue, Webcast, Patient, Pediatrics, Adrenaline, Population growth, Prescription, Irritation, Face, Pharmaceutical industry

The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.

Key Points: 
  • The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.
  • Of the patients that do fill their prescription, 80-90% either do not carry or use their treatment as indicated.
  • In late-February, the Company announced positive clinical data from a Phase 2 trial evaluating neffy in adults with chronic spontaneous urticaria.
  • The webcast replay and accompanying slides from today’s investor event may be accessed through the Events & Presentations page in the Investors & Media section of the Company's website.